118 completed, 9 terminated, 7 unknown, 4 recruiting. 69 Phase 1, 30 Phase 2, 22 Phase 3, 15 Phase 4, 10 Not applicable.
Follow Orion Corporation, Orion Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial to Study the Safety, Pharmacokinetics and Preliminary Antitumour Activity of ODM-216 in Patients With Cancer ODM-216 - Advanced Solid Tumors Cancer | Phase 1 / Phase 2 | Recruiting | Orion Corporation, Orion Pharma | 195 | 2026-09-03 | 2026-09-24 |
| A 2-part Phase 1/2 Open-label Trial on ODM-212 ODM-212, Ipilimumab and nivolumab, Gemcitabine and nab-paclitaxel - Mesothelioma, Pancreatic Cancer | Phase 1 / Phase 2 | Recruiting | Orion Corporation, Orion Pharma | 229 | 2026-03-27 | 2026-10-22 |
| A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008) [¹⁴C]Opevesostat, Prednisone, Fludrocortisone - Metastatic Prostate Cancer | Phase 1 | Completed | Merck Sharp & Dohme LLC | 8 | 2024-09-19 | 2024-10-23 |
| Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) Opevesostat, Olaparib, Docetaxel - Prostatic Neoplasms, Castration-Resistant | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 220 | 2024-05-20 | 2026-10-21 |
| A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001) Opevesostat, Dexamethasone, Fludrocortisone - Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer | Phase 1 | Completed | Merck Sharp & Dohme LLC | 14 | 2024-01-30 | 2026-03-19 |
| A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005) Opevesostat, Dexamethasone, Fludrocortisone acetate - Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer | Phase 1 | Completed | Merck Sharp & Dohme LLC | 7 | 2023-11-14 | 2026-04-27 |
| A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours ODM-212 - Solid Tumours | Phase 1 / Phase 2 | Recruiting | Orion Corporation, Orion Pharma | 315 | 2023-10-26 | 2026-05-08 |
| Levosimendan as Treatment of Aneurysmal SubArachnoid Haemorrhage Levosimendan, Placebo - Sub-arachnoid Haemorrhage | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 30 | 2023-10-13 | 2026-08-31 |
| Efficacy and Tolerability of Tasipimidine in Sleepless Patients Tasipimidine, Tasipimidine placebo - Insomnia | Phase 2 | Completed | Orion Corporation, Orion Pharma | 190 | 2023-08-20 | 2025-10-22 |
| Efficacy and Safety of Remo-Wax® Oil (RWO) in Subjects With Isolated Itching of the External Ear Canal Remo-Wax® Oil - Itching | Not applicable | Completed | Orion Corporation, Orion Pharma | 36 | 2023-05-17 | 2023-10-06 |
| Study to Compare Relative Bioavailability of 3 Indacaterol/Glycopyrronium Test Products and Reference Product Indacaterol/glycopyrronium - Healthy Volunteers | Phase 1 | Completed | Orion Corporation, Orion Pharma | 24 | 2022-02-28 | 2022-07-13 |
| Comparison of Tiotropium Absorption From Tiotropium Easyhaler and Spiriva HandiHaler Tiotropium Bromide Monohydrate - Healthy Volunteers | Phase 1 | Completed | Orion Corporation, Orion Pharma | 88 | 2022-02-16 | 2022-08-18 |
| Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing Buventol® Easyhaler® 200 µg/inhalation dmDPI, Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI, Ventoline® Evohaler® 100 µg/inhalation pMDI - Asthma | Phase 4 | Completed | Orion Corporation, Orion Pharma | 180 | 2021-11-11 | 2023-09-05 |
| Effect of Electronic Monitoring and Feedback on Adherence to Easyhaler Controller Medication in Patients With Asthma Reminders and feedback to improve adherence, No reminders and feedback to improve adherence - Asthma | Phase 4 | Completed | Orion Corporation, Orion Pharma | 158 | 2021-06-23 | 2024-11-04 |
| Absorption of Indacaterol and Glycopyrronium From Ultibro Breezhaler Indacaterol maleate and glycopyrronium bromide, Ultibro Breezhaler with oral charcoal - Healthy Volunteers | Phase 1 | Completed | Orion Corporation, Orion Pharma | 34 | 2021-05-07 | 2021-09-28 |
| Pharmacokinetic Study Comparing Tiotropium Easyhaler® and Spiriva® HandiHaler® Tiotropium Bromide Monohydrate, Tiotropium Easyhaler with oral activated charcoal - Healthy Volunteers | Phase 1 | Completed | Orion Corporation, Orion Pharma | 43 | 2021-04-26 | 2021-10-25 |
| Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer Darolutamide (Nubeqa, BAY1841788), Placebo, Androgen deprivation therapy (ADT) - Prostatic Neoplasms | Phase 3 | Completed | Bayer | 669 | 2021-02-23 | 2026-09-29 |
| Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in Norway Budesonide-Formoterol - Asthma, COPD | Terminated | Orion Corporation, Orion Pharma | 29 | 2020-12-10 | 2021-09-23 | |
| Blood-Brain Barrier Penetration of Therapeutic Agents in Human ODM-104, Paracetamol - CNS Disease | Phase 1 | Completed | Orion Corporation, Orion Pharma | 4 | 2020-10-29 | 2021-04-13 |
| Spanish Randomized Clinical Trial to Compare Levosimendan Versus Placebo in Postoperative Cardiac Surgery (SPARTANS) Levosimendan, Placebos - Cardiac Output, Low | Phase 2 / Phase 3 | Unknown | María de los Ángeles Tena Pajuelo | 300 | 2020-06-17 | 2020-07-24 |
Showing 20 of 141. Sign in to see all of them.
Asthma (22) · Parkinson Disease (12) · Prostatic Neoplasms (10) · Heart Failure (7) · Pulmonary Disease, Chronic Obstructive (5) · Amyotrophic Lateral Sclerosis (3) · Alzheimer Disease (2) · Coronary Artery Disease (2) · Hip Fractures (2) · Pain (2) · Stroke (2) · Acute Coronary Syndrome (1) · Acute Kidney Injury (1) · Aneurysm (1) · Behavioral Symptoms (1)
Simendan (21) · Budesonide (12) · Charcoal (11) · carbidopa, levodopa drug combination (11) · ORM-12741 (10) · Carbidopa (9) · Levodopa (9) · darolutamide (9) · Budesonide, Formoterol Fumarate Drug Combination (7) · Dexmedetomidine (7) · Stalevo (7) · entacapone (7) · Formoterol Fumarate (4) · Midazolam (4) · fludrocortisone acetate (4)
Finland (76) · Germany (27) · United Kingdom (24) · France (21) · Sweden (14) · Netherlands (13) · Spain (13) · United States (13) · Italy (10) · Belgium (9) · Canada (8) · Australia (7) · Austria (6) · Denmark (6) · Estonia (6)
Mika Scheinin, MD (5) · Ulla Sairanen, MSc (5) · Karim Fizazi (4) · Rainard Fuhr, MD (4) · Juha Rinne, MD, PhD (3) · Kimmo Ingman, MD, PhD (3) · Leena Mattila, MD, PhD (3) · Juha Peltonen, MD (2) · Juha Rinne, Prof (2)
PMID 22436955, PMID 24974051, PMID 25887576, PMID 28753851, PMID 34536404, PMID 34866168, PMID 38170393, PMID 10093980, PMID 11069188, PMID 17473298, PMID 18405408, PMID 18795253, PMID 19054201, PMID 19539144, PMID 19700350, PMID 20582993, PMID 22030215, PMID 23620700, PMID 24126568, PMID 24489014, PMID 24621834, PMID 24920349, PMID 26082815, PMID 27817813, PMID 28753849, PMID 29502195, PMID 29718383, PMID 30763142, PMID 30824559, PMID 31315908, PMID 31571095, PMID 32905676, PMID 32989226, PMID 33262202, PMID 33296042, PMID 33554636, PMID 34797506, PMID 35179323, PMID 35324507, PMID 35656777, PMID 36087070, PMID 36606032, PMID 36795843, PMID 37222151, PMID 37448694, PMID 37660438, PMID 38320513, PMID 38394384, PMID 38487037, PMID 39279580
2014 (2), 2015 (2), 2016 (2), 2019 (2), 2005 (1), 2008 (1), 2017 (1), 2023 (1)